Polymorphism in the promoter region of the α(2A) adrenergic receptor gene and mood disorders

NeuroReport

Volumn 9, Issue 7, 1998, Pages 1291-1294

  Ohara, Koichi ^a   Nagai, Miho ^a   Tani, Kunihiko ^a   Tsukamoto, Toshio ^a   Suzuki, Yasuo ^a   Ohara, Kenshiro ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Depression; Gene; Mood disorders; Polymorphism; Promoter; (2A) Adrenergic receptor

Indexed keywords

ALPHA 2A ADRENERGIC RECEPTOR;

ADULT; AFFECTIVE NEUROSIS; ALLELE; ALPHA ADRENERGIC STIMULATION; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; FAMILY HISTORY; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; RECEPTOR GENE; SUICIDE ATTEMPT;

EID: 0032507645     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-199805110-00006     Document Type: Article

References (25)

1. Ruffolo RR Jr, Nichols AJ, Stadel JM and Hieble JP. Ann Rev Pharmacol Toxicol 32, 243-279 (1993).
2. Potter WZ and Manji HK. Clin Chem 40, 279-287 (1994).
3. Schatzberg AF and Schildkraut JJ. Recent studies on norepinephrine system in mood disorders. In Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press, 1995: 911-920.
4. Piletz JE Schubert DSP and Halaris A. Life Sci 39, 1589-1616 (1986).
5. Boyajian CL and Leslie FM. J Pharmacol Exp Ther 241, 1092-1098 (1987).
6. Bricca G. Dontenwill M, Molines A et al. Eur J Pharmacol 162, 1-9 (1989).
7. Meeley MP, Towle AC, Ernsberger P et al. Hypertension 13, 341-351 (1989).
8. Grossman F, Manji HK and Potter WZ. J Psychopharmacol 7, 4-18 (1993).
9. Wolfe N, Cohen BM and Gelenberg AJ. Psychiatry Res 20, 107-116 (1987).
10. Katona CLE, Theodorou AE, Davis SL et al. J Affect Dis 17, 219-228 (1989).
11. Daiguji M, Meltzer HY, Tong C et al. Life Sci 29, 2059-2064 (1981).
12. Stahl SM, Lemoine PM, Ciaranello RD and Berger PA. Psychiatry Res 10, 157-164 (1983).
13. Siever LJ, Kafka MS, Targum SM et al. Psychiatry Res 11, 287-302 (1984).
14. Pandy GN, Pandey SC and Davis JM. Pharmacol Toxicol Suppl 3, 313-336 (1990).
15. García-Sevilla JA, Padró D, Giralt T et al. Arch Gen Psychiatry 47, 125-132 (1990).
16. Baumann PA and Mautre L. Naunyn-Schemiedeberg's Arch Pharmacol 300, 31-37 (1977).
17. Charney DS, Heninger GR and Sternberg DE. Br J Psychiatry 144, 407-416 (1984).
18. Katsuda Y. Jpn J Neuropsychopharmacol 14, 313-318 (1992).
19. Bylund DB, Eikenberg DC, Hieble JP et al. Pharmacol Rev 46, 121-136 (1994).
20. Lorenz W, Lomansney JW, Collins S et al. Mol Pharmacol 38, 599-603 (1990).
21. Lario S, Calls J, Cases A et al. Clin Genet 51, 129-130 (1997).
22. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disease, 4th edn. Washington, DC: American Psychiatric Press, 1994. (Translated into Japanese by Takahashi S, Ohno H, and Someya T, Tokyo: Igaku-Shoin Ltd., 1995).
23. Endicott J and Spitzer RL. Arch Gen Psychiatry 35, 37-844 (1978).
24. Wang L, Hirayasu K, Ishizawa M and Kobayashi Y. Nucl Acids Res 22, 1774-1775 (1994).
25. Wang Z, Crawe RR, Tanna VL and Winokur G. J Affect Dis 25, 191-196 (1992).